S&P 500   5,246.74
DOW   39,826.92
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,246.74
DOW   39,826.92
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,246.74
DOW   39,826.92
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
S&P 500   5,246.74
DOW   39,826.92
QQQ   444.85
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
7 Stocks That Will Drive the Weight Loss Drugs Market
NASDAQ:GRFS

Grifols (GRFS) Stock Price, News & Analysis

$6.55
-0.10 (-1.50%)
(As of 08:56 AM ET)
Today's Range
$6.55
$6.55
50-Day Range
$5.47
$9.34
52-Week Range
$5.30
$12.15
Volume
3,008 shs
Average Volume
3.35 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Grifols MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
57.9% Upside
$10.50 Price Target
Short Interest
Healthy
3.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Grifols in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
63.27%
From $0.98 to $1.60 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.18 out of 5 stars

GRFS stock logo

About Grifols Stock (NASDAQ:GRFS)

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

GRFS Stock Price History

GRFS Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
GRFS Nov 2024 3.000 put
GRFS Apr 2024 11.000 call
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Grifols price target raised by EUR 0.80 at Berenberg
GRFS Apr 2024 6.000 put
GRFS Apr 2024 10.000 put
Gotham City Research renews short-sell attack on Grifols
See More Headlines
Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/04/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GRFS
Employees
26,314
Year Founded
1909

Price Target and Rating

Average Stock Price Target
$10.50
High Stock Price Target
$10.50
Low Stock Price Target
$10.50
Potential Upside/Downside
+57.9%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$131.34 million
Pretax Margin
3.40%

Debt

Sales & Book Value

Annual Sales
$7.13 billion
Cash Flow
$0.83 per share
Book Value
$12.61 per share

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
0.57

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Thomas H. Glanzmann (Age 66)
    CEO & Executive Chairman
    Comp: $164.14k
  • Mr. Alfredo Arroyo Guerra (Age 66)
    CFO & VP
  • Mrs. Eva Bastida Tubau
    Corporate Vice President and Director of Scientific & Medical Affairs
  • Ms. Nuria Pascual Lapeña (Age 60)
    VP of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer
  • Mr. David Ian Bell (Age 70)
    Chief Corporate Development, Legal & Data Protection Officer
  • Ms. Maria Teresa-Rioné Llano (Age 59)
    Chief Communications Officer
  • Ms. Montserrat Gaja Llamas (Age 59)
    Chief Human Resources Officer
  • Mr. Vicente Blanquer Torre (Age 63)
    Chief Quality Officer
  • Mr. Alberto Grifols Roura (Age 65)
    President of the Bio Supplies Division
  • Mr. Sergio Roura Adell (Age 56)
    President of Commercial Tech Support

GRFS Stock Analysis - Frequently Asked Questions

Should I buy or sell Grifols stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" GRFS shares.
View GRFS analyst ratings
or view top-rated stocks.

What is Grifols' stock price target for 2024?

3 equities research analysts have issued twelve-month price targets for Grifols' stock. Their GRFS share price targets range from $10.50 to $10.50. On average, they expect the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 57.9% from the stock's current price.
View analysts price targets for GRFS
or view top-rated stocks among Wall Street analysts.

How have GRFS shares performed in 2024?

Grifols' stock was trading at $11.56 at the beginning of the year. Since then, GRFS shares have decreased by 42.5% and is now trading at $6.65.
View the best growth stocks for 2024 here
.

Are investors shorting Grifols?

Grifols saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 8,190,000 shares, an increase of 11.3% from the February 29th total of 7,360,000 shares. Based on an average daily trading volume, of 3,220,000 shares, the days-to-cover ratio is presently 2.5 days. Currently, 3.2% of the company's shares are sold short.
View Grifols' Short Interest
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) released its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported $0.21 EPS for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The biotechnology company had revenue of $1.43 billion for the quarter. Grifols had a trailing twelve-month return on equity of 1.73% and a net margin of 1.84%.

What ETF holds Grifols' stock?

First Trust NYSE Arca Biotechnology Index Fund holds 4,612,158 shares of GRFS stock, representing 3.48% of its portfolio.

When did Grifols' stock split?

Shares of Grifols split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Grifols issued on next quarter's earnings?

Grifols updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.6 billion-, compared to the consensus revenue estimate of $7.7 billion.

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Grifols own?
Who are Grifols' major shareholders?

Grifols' stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (0.00%), Brandes Investment Partners LP (0.00%), Flat Footed LLC (0.00%), First Trust Advisors LP (0.00%), Whitebox Advisors LLC (0.00%) and Harris Associates L P (0.00%).

How do I buy shares of Grifols?

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Grifols have any subsidiaries?
The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..
Read More
This page (NASDAQ:GRFS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners